ABCANN GLOBAL CORPORATION (TSXV: ABCN) (“ABcann” or the “Company”) is pleased to announce that its wholly-owned subsidiary, ABcann Australia Pty Ltd. (“ABcann Australia”), has received an import license from the Federal Office of Drug Control in Australia.
TheSeedInvestor
ABCANN GLOBAL CORPORATION (TSXV: ABCN) (“ABcann” or the “Company”) is pleased to announce that its wholly-owned subsidiary, ABcann Australia Pty Ltd. (“ABcann Australia”), has received an import license from the Federal Office of Drug Control in Australia. ABcann continues to work with government and its industry partners in Australia to develop exclusive programs targeting physician networks. Following receipt of any necessary approvals, including the approval of the TSX Venture Exchange, ABcann intends to supply medicinal cannabis to the Australian market via the Australian Department of Health’s TGA (Therapeutic Goods Administration) Special Access Scheme.

“This import license is a key milestone towards generating revenue through ABcann’s network of physicians, pharmacists and patients, and advancing the use of medical cannabis,” commented Barry Fishman, Chief Executive Officer of ABcann. “We view Australia as an important emerging market for medical cannabis and I look forward to meeting with our strategic partners and stakeholders in Australia later this month to further discuss opportunities there.”

“Attainment of this license is one of several important steps we have taken over the last six months to cement key relationships with strategic partners in industry and government. ABcann Australia is committed to providing Australian patients with high quality medicinal cannabis products,” said Henry Pinskier, MD, Chairman of ABcann Australia.

About ABcann:

ABcann holds production and sales licenses from Health Canada. Its flagship facility in Napanee, Ontario contains proprietary plant-growing technology, centred on its specially designed, environmentally-controlled growing chambers. This approach results in the production of pharmaceutical-grade cannabis products. 

The Company is expanding its cultivation capacity and pursuing partnerships and product development opportunities domestically, as well as in select international markets, such as Germany, Australia and Israel.

ON BEHALF OF THE BOARD OF DIRECTORS
"Barry Fishman"
Barry Fishman
CEO and Director

For further information, please contact:

Barry Fishman (CEO and Director) at barry.fishman@abcannglobal.com
Michael Bumby (CFO) at michael.bumby@abcannglobal.comNeither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Please see full disclaimers on the TheSeedInvestor.com website applicable to all content provided by TSI, wherever published or re-published: http://theseedinvestor.com/about/disclaimerDisclaimer.

This news release/advertorial is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed on this website unless you can afford to lose your entire investment. Also, investing in small-cap and micro-cap securities is highly speculative and carries an extremely high degree of risk. This website makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Compensation: A thirty-six-thousand-dollar investor relations budget is being managed by The Seed Investor. Any funds leftover after expenses for research, overhead, advertising and public relations related to InMed Pharmaceuticals Inc. (ticker symbol (CSE: IN; OTCQB: IMLFF) will be considered profit. The Seed Investor and/or entities related to The Seed Investor hold shares in (CSE: IN; OTCQB: IMLFF) and intend to sell those shares. Please review all investment decisions with a licensed inv­estment advisor. 
 
32x32x1   32x32x2   32x32x3
TheSeedInvestor.com
9375 E Shea Blvd Ste 100
Scottsdale 85260
info@theseedinvestor.com
 
©2018, All Rights Reserved  |  Unsubscribe   |   View this in Browser

To keep receiving emails from us, please add us to your address book.